Lewes, DE -- (SBWIRE) -- 08/31/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: THL Credit, Inc. (NASDAQ:TCRD), Fortinet Inc (NASDAQ:FTNT), ARRIS GROUP DL-, 01(NASDAQ:ARRS), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).
THL Credit, Inc. (NASDAQ:TCRD) decreased -0.76% and closed at $15.07 on a traded volume of 1.124 million shares, in comparison to 257,429 shares of average trading volume. So far this year, the stock is up over 6.15%.
The company has a total market capitalization of $532.31 Million and its total outstanding shares are 33.91 million.
Will TCRD Get Buyers Even After The Recent Rally? Find Out Here
THL Credit, Inc. is a non-diversified, closed-end management investment company. It operates as a business development company.
Fortinet Inc (NASDAQ:FTNT) plunged -1.25% and closed at $19.80 on a traded volume of 1.12 million shares, whereas its average trading volume is 2.08 million shares. In the last three months, the stock is up 2.64%. The Intra-day range for the stock is $19.70 and $20.26.
Will FTNT Get Buyers Even After The Recent Rally? Find Out Here
Fortinet, Inc. (Fortinet) provides network security solutions. Through the Company’s products and subscription services, Fortinet provides integrated and protection against security threats for enterprises
ARRIS GROUP DL-, 01(NASDAQ:ARRS) dropped -1.26% and closed at $15.76. So far in three months, the stock is up 2.08%. The 52-week range for the stock is $12.40 and $17.98 and during the previous trading session the stock touched its highest price at $15.88. Its introductory price for the day was $15.83, with the overall traded volume of 1.11 million shares.
Will ARRS Get Buyers Even After The Recent Rally? Find Out Here
Arris Enterprises, Inc. develops, manufactures, and supplies telephony, data, video, construction, rebuild, and maintenance equipment primarily for cable system operators in the broadband communications industry worldwide. The company operates in three segments
Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX) after opening its shares at the price of $2.55, dropped -2.35% to close at $2.49 for the day. The stock moved on a traded volume of 1.11 million shares, in comparison to 731,806 shares of average trading volume.
The 52-week range for the stock is $1.55 and $2.76 and during the previous trading session the stock touched its highest price at $2.58.
Will LXRX Get Buyers Even After The Recent Rally? Find Out Here
Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.
About LeadingStockAlerts
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
Disclaimer
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/